264 related articles for article (PubMed ID: 19804967)
1. The role of (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma.
Moon CM; Bang S; Chung JB
Surg Oncol; 2011 Mar; 20(1):e10-7. PubMed ID: 19804967
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
[TBL] [Abstract][Full Text] [Related]
3. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.
Kluge R; Schmidt F; Caca K; Barthel H; Hesse S; Georgi P; Seese A; Huster D; Berr F
Hepatology; 2001 May; 33(5):1029-35. PubMed ID: 11343227
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.
Kim JY; Kim MH; Lee TY; Hwang CY; Kim JS; Yun SC; Lee SS; Seo DW; Lee SK
Am J Gastroenterol; 2008 May; 103(5):1145-51. PubMed ID: 18177454
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma.
Kim YJ; Yun M; Lee WJ; Kim KS; Lee JD
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1467-72. PubMed ID: 14579085
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer.
Corvera CU; Blumgart LH; Akhurst T; DeMatteo RP; D'Angelica M; Fong Y; Jarnagin WR
J Am Coll Surg; 2008 Jan; 206(1):57-65. PubMed ID: 18155569
[TBL] [Abstract][Full Text] [Related]
8. FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma.
Ruys AT; Bennink RJ; van Westreenen HL; Engelbrecht MR; Busch OR; Gouma DJ; van Gulik TM
HPB (Oxford); 2011 Apr; 13(4):256-62. PubMed ID: 21418131
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
10. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
Buchmann I; Ganten TM; Haberkorn U
Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
[TBL] [Abstract][Full Text] [Related]
11. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis.
Hu JH; Tang JH; Lin CH; Chu YY; Liu NJ
J Investig Med; 2018 Jan; 66(1):52-61. PubMed ID: 28912249
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance and Prognostic Relevance of FDG Positron Emission Tomography/Computed Tomography for Patients with Extrahepatic Cholangiocarcinoma.
Kim NH; Lee SR; Kim YH; Kim HJ
Korean J Radiol; 2020 Dec; 21(12):1355-1366. PubMed ID: 32767862
[TBL] [Abstract][Full Text] [Related]
13. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer.
Kato T; Tsukamoto E; Kuge Y; Katoh C; Nambu T; Nobuta A; Kondo S; Asaka M; Tamaki N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1047-54. PubMed ID: 12173019
[TBL] [Abstract][Full Text] [Related]
14. [18F-FDG PET/CT in staging and restaging cholangiocarcinoma].
Notaristefano A; Niccoli Asabella A; Stabile Ianora AA; Merenda N; Moschetta M; Antonica F; Altini C; Ferrari C; Cesarano E; Rubini G
Recenti Prog Med; 2013; 104(7-8):328-35. PubMed ID: 24042402
[TBL] [Abstract][Full Text] [Related]
15. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.
Huang X; Yang J; Li J; Xiong Y
Medicine (Baltimore); 2020 Aug; 99(35):e20932. PubMed ID: 32871859
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Mori A; Doi R; Ikai I; Uemoto S
Surgery; 2008 Jun; 143(6):769-77. PubMed ID: 18549893
[TBL] [Abstract][Full Text] [Related]
17. Value of PET/CT in the management of primary hepatobiliary tumors, part 2.
Sacks A; Peller PJ; Surasi DS; Chatburn L; Mercier G; Subramaniam RM
AJR Am J Roentgenol; 2011 Aug; 197(2):W260-5. PubMed ID: 21785051
[TBL] [Abstract][Full Text] [Related]
18. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer.
Park MS; Lee SM
Anticancer Res; 2014 May; 34(5):2551-4. PubMed ID: 24778075
[TBL] [Abstract][Full Text] [Related]
19. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.
Petrowsky H; Wildbrett P; Husarik DB; Hany TF; Tam S; Jochum W; Clavien PA
J Hepatol; 2006 Jul; 45(1):43-50. PubMed ID: 16690156
[TBL] [Abstract][Full Text] [Related]
20. FDG PET in the diagnosis of hilar cholangiocarcinoma.
Fritscher-Ravens A; Bohuslavizki KH; Broering DC; Jenicke L; Schäfer H; Buchert R; Rogiers X; Clausen M
Nucl Med Commun; 2001 Dec; 22(12):1277-85. PubMed ID: 11711897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
